Most of the huge groundswell for the two most common diabesity drugs — Eli Lilly’s tirzepatide and Novo Nordisk’s semaglutide — has been driven by
Read MoreTag: Mounjaro
As FDA Approves Zepbound, Woman Shares Mounjaro Weight Loss
People with obesity or who are overweight and hoping to lose weight with the assistance of medication have a new option. On Nov. 8, the
Read More
Eli Lilly Stock: Is LLY Stock A Buy After Mounjaro Drives A Strong Third-Quarter Beat?
Eli Lilly (LLY) stock retook its 50-day moving average in early November after diabetes drug, Mounjaro, helped drive a third-quarter beat. X Before yearend, analysts
Read More